Guangdong Biolight Meditech Co Ltd

Guangdong Biolight Meditech Co Ltd has a market price of 21.23 CNY and a market capitalization of 5,617,589,137.71 CNY, with a price-to-book ratio of 4.94 and a price-to-tangible-book ratio of 4.94. The company's liquidity is assessed as medium, with a current ratio of 1.59 and a debt-to-equity ratio of 0.64. Despite a negative net cash position after subtracting total debt, the company reported an operating cash flow of 90,442,530 CNY. The company's profitability is weak, with a net loss of 69,427,750 CNY and an operating loss of 72,624,880 CNY. Return on equity is -6.1%, and return on assets is -2.75%. These figures indicate that the company is underperforming relative to the industry's preferred metrics for profitability and returns. Guangdong Biolight Meditech Co Ltd's revenue is not segmented by geographic region or product line in the available data. However, the company's total revenue of 1,095,390,750 CNY suggests a concentration in a single business model or market. The company's growth trajectory is uncertain, with no specific numeric deltas provided for the current or next fiscal year. The company's free cash flow is negative at -187,961,080 CNY, and capital expenditure is -167,463,150 CNY, indicating a significant investment in infrastructure or expansion. The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The key flag of negative net cash after subtracting total debt suggests potential liquidity constraints. No specific dilution sources are identified in the available data. No recent events, such as filings or transcripts, are provided in the available data to inform the company's current status or strategic direction.